Linola H N

Prednisolone, the active ingredient in Linola H N, is a corticosteroid presented as a topical preparation for skin application. It reduces inflammation and modulates immune responses in dermatologic conditions such as eczema, psoriasis and allergic reactions.

GNH USA supplies Linola H N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Prednisolone is a corticosteroid used to treat inflammatory and immune‑mediated skin conditions.

- Atopic dermatitis: reduces redness, itching and swelling associated with the condition. - Psoriasis: diminishes plaque formation and erythema. - Contact dermatitis: alleviates irritation caused by allergens or irritants. - Allergic skin reactions: suppresses localized immune response and limits edema.

Topical prednisolone may cause a range of local and systemic reactions.

Common Side Effects: - Skin irritation or burning sensation at the application site. - Dryness or peeling of the treated skin. - Acne‑like eruptions. - Temporary hypopigmentation.

Serious or Rare Side Effects: - Skin atrophy or striae formation with prolonged use. - Secondary infection of the treated area. - Systemic adrenal suppression, especially when large areas are treated or occlusion is used.

When using Linola H N, consider the following safety measures.

- Assess infection: avoid application on infected skin unless combined with appropriate antimicrobial therapy. - Limit duration: restrict continuous use to the shortest period necessary to control symptoms. - Avoid occlusion: do not cover treated areas with airtight dressings unless directed by a clinician. - Monitor for systemic effects: watch for signs of adrenal insufficiency in extensive or prolonged therapy. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Prednisolone may interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent use can increase risk of systemic side effects. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic prednisolone levels.

Moderate Interactions (Monitor Closely): - Antiviral agents such as acyclovir: may require monitoring for delayed wound healing. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined use can increase risk of skin irritation.